As agonist activation of MOR within respiratory centers in the medulla and brainstem is known to mediate opioid respiratory depression [22], the targeted delivery of a potent antagonist to MOR in the brain would be a potentially valuable tool to reverse opioid respiratory depression and overdose [23,24,25,26,27]. Here, OPRM1 is linked to Respiratory insufficiency due to muscle weakness.